John P. Leonard, Stephen J. Schuster, Christos Emmanouilides, Felix Couture, Nick Teoh, William A. Wegener, Morton Coleman and David M. Goldenberg Durable complete responses from therapy with combined epratuzumab and rituximab Cancer 113
Article first published online: 13 OCT 2008 | DOI: 10.1002/cncr.23890
In this international, multicenter trial, combined rituximab (anti-CD20) and epratuzumab (humanized anti-CD22 antibody) induced durable responses in patients with recurrent, indolent non-Hodgkin lymphoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field